ReviewPharmaceutical biology2020
Chinese medicinal plants for the potential management of high-altitude pulmonary oedema and pulmonary hypertension.
Review in Pharmaceutical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Assessing Dazhu Hongjingtian: Protection Against Acute Hypoxic Organ Damage and Analysis of Its Main Pharmaceutical Components.Biomedical chromatography : BMC · 2026Article
- Traditional Chinese medicine constitution characteristics and influencing factors for acute mountain sickness susceptibility in rapidly ascending high-altitude populations: a cross-sectional survey.Journal of health, population, and nutrition · 2026Article
- The clinical efficacy and mechanism of Rhodiola rosea in treating rheumatoid arthritis in high-altitude areas by regulating the HIF-1α signaling pathway.Frontiers in medicine · 2026Article
- Acute mountain sickness prediction: a concerto of multidimensional phenotypic data and machine learning strategies in the framework of predictive, preventive, and personalized medicine.The EPMA journal · 2025Article
- Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review.The open respiratory medicine journal · 2025Review
- Zhishi Xiebai Guizhi Decoction modulates hypoxia and lipid toxicity to alleviate pulmonary vascular remodeling of pulmonary hypertension in rats.Chinese medicine · 2024Article
- Cardiovascular Effects of a Glycosylated Flavonoids-Rich Leaf Extract from BrazilianPharmaceuticals (Basel, Switzerland) · 2024Article
- Promising Natural Medicines for the Treatment of High-Altitude Illness.High altitude medicine & biology · 2023Review
- Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities.Current issues in molecular biology · 2023Review
- Protective effects of areca nut polyphenols on hypoxic damage of rat pulmonary microvascular endothelial cells.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Article
- Role of Solid Lipid Nanoparticles for the Delivery of Lipophilic Drugs and Herbal Medicines in the Treatment of Pulmonary Hypertension.Pharmaceutical nanotechnology · 2022Review
- Prevention and Treatment of Cardiovascular Diseases with Plant Phytochemicals: A Review.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextDespite the abundance of knowledge regarding high-altitude pulmonary edoema (HAPE) and high-altitude pulmonary hypertension (HAPH), their prevalence continues to be on the rise. Thus, there is an urgent need for newer safe, effective, and relatively economic drug candidates. China is particularly known for the use of medicinal plants.
objectiveThis review summarizes the medicinal plants used for HAPE and HAPH in the past 30 years, as well as some potential plants.
methodsPublications on HAPE and HAPH from 1990 to 2020 were identified using Web of Science, PubMed, SCOPUS, Springer Link, Google Scholar databases, Chinese Clinical Trial Registry and CNKI with the following keywords: 'medicinal plants,' 'hypoxia,' 'high altitude pulmonary edema,' 'high altitude pulmonary hypertension,' 'pathophysiology,' 'mechanisms,' 'prevention,' 'treatment,' 'human,' 'clinical,' 'safety,' and 'pharmacokinetics.'
resultsWe found 26 species (from 20 families) out of 5000 plants which are used for HAPE and HAPH prevention or treatment. DISCUSSION AND
conclusionsWe mainly reviewed the medicinal plants and mechanisms for the treatment of HAPE and HAPH, and we also assessed related toxicology experiments, pharmacokinetics and bioavailability. Potential medicinal plants were also identified. Further research is needed to determine the pharmacological effects and active ingredients of these potential medicinal plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.